Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib delayed-start phase IIa trial in adult idiopathic inflammatory myopathy
2019-003868-42Phase 2Unknown
- Sponsor
- The University of Manchester
- Start
- Mar 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in Autoimmune Myopathies, polymyositis (PM) and dermatomyositis (DM) (2 arms), sponsored by The University of Manchester. Primary endpoint: Minimal clinical response at 24 weeks of active treatment. Status: unknown.
02
Drugs
baricitinib
03
Conditions
Autoimmune Myopathiespolymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on 2019-003868-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003868-42.